Tidal Investments LLC Has $556,000 Holdings in Natera, Inc. (NASDAQ:NTRA)

Tidal Investments LLC cut its position in Natera, Inc. (NASDAQ:NTRA) by 74.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,377 shares of the medical research company’s stock after selling 12,539 shares during the quarter. Tidal Investments LLC’s holdings in Natera were worth $556,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Covestor Ltd lifted its stake in Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. GAMMA Investing LLC boosted its stake in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after buying an additional 106 shares in the last quarter. CIBC Asset Management Inc raised its stake in Natera by 3.3% during the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after acquiring an additional 111 shares in the last quarter. RiverPark Advisors LLC lifted its holdings in shares of Natera by 3.5% in the third quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after acquiring an additional 112 shares during the last quarter. Finally, Moss Adams Wealth Advisors LLC boosted its stake in shares of Natera by 5.4% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after purchasing an additional 135 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Trading Up 2.4 %

NTRA opened at $161.88 on Monday. The company has a fifty day moving average price of $147.43 and a two-hundred day moving average price of $126.58. Natera, Inc. has a 1-year low of $58.21 and a 1-year high of $175.63. The company has a market cap of $21.37 billion, a P/E ratio of -91.98 and a beta of 1.63. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same period in the prior year, the business earned ($0.95) EPS. The firm’s revenue for the quarter was up 63.9% on a year-over-year basis. Analysts predict that Natera, Inc. will post -1.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on NTRA. Canaccord Genuity Group increased their price objective on shares of Natera from $150.00 to $165.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Craig Hallum boosted their price objective on Natera from $121.00 to $157.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. TD Cowen lifted their price target on Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to MarketBeat, Natera currently has an average rating of “Moderate Buy” and a consensus target price of $152.67.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 4,523 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total value of $589,799.20. Following the transaction, the chief executive officer now owns 191,163 shares of the company’s stock, valued at approximately $24,927,655.20. This trade represents a 2.31 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Jonathan Sheena sold 3,000 shares of Natera stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $125.67, for a total value of $377,010.00. Following the transaction, the insider now owns 57,432 shares of the company’s stock, valued at $7,217,479.44. This trade represents a 4.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 130,263 shares of company stock valued at $20,905,668. 7.60% of the stock is owned by company insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.